Trials / Completed
CompletedNCT04270370
A Study of LY3478045 in Healthy Participants
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single-and Multiple Ascending Doses of LY3478045in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3478045 and any side effects that might be associated with it. The study will also measure how much LY3478045 gets into the bloodstream and how long it takes the body to get rid of it. This study has two parts: Part A (one dose) will last about six weeks and Part B (more than one dose) will last about eight weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3478045 | Administered orally. |
| DRUG | Placebo | Administered orally. |
| DRUG | Atorvastatin | Administered orally. |
Timeline
- Start date
- 2020-03-16
- Primary completion
- 2021-06-23
- Completion
- 2021-06-23
- First posted
- 2020-02-17
- Last updated
- 2024-07-25
- Results posted
- 2024-07-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04270370. Inclusion in this directory is not an endorsement.